|Title:||Therapeutic compositions for intranasal administration which include KETOROLAC|
|Abstract:||An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.|
|Inventor(s):||Santus; Giancarlo (Milan, IT), Bottoni; Giuseppe (Bergamo, IT), Bilato; Ettore (Padova, IT)|
|Assignee:||Recordati Ireland Limited (IE)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Formulation; Compound; Dosage form;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Italy||MI91A2024||Jul 22, 1991|
|Country||Document Number||Publication Date|
|Austria||130758||Dec 15, 1995|
|Germany||69206345||Jan 11, 1996|
|Denmark||0524587||Apr 09, 1996|
|European Patent Office (EPO)||0524587||Jan 27, 1993|
|Spain||2082288||Mar 16, 1996|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.